Skip to main content

Table 3 Patient Outcomes

From: Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study

Outcome

PCC3 (n = 57)

PCC4 (n = 23)

p

Patients achieving INR ≤ 1.5, n (%)

18 (31.6%)

20 (87.0%)

< 0.001

 Intracranial bleeding

10 (32.3%)

16 (84.2%)

 

 Gastrointestinal bleeding

4 (40.0%)

2 (100%)

 

 Other bleeding

4 (75%)

2 (100%)

 

Death during hospitalization, n (%)

14 (24.7%)

8 (34.8%)

0.52

 Intracranial bleeding

10 (32.3%)

7 (36.8%)

 

 Gastrointestinal bleeding

1 (10.0%)

0 (0%)

 

 Other bleeding

3 (75%)

1 (50%)

 

Length of stay

 Overall

6.0 (4.0–11.0)

6.0 (2.5–10.0)

0.47

 Survivors

6.5 (4.0–10.0)

6.0 (3.0–9.5)

0.52

Thromboembolic events, n (%)

5 (8.8%)

2 (8.7%)

1.0

  1. INR international normalized ratio, PCC prothrombin complex concentrate, PCC3 3-factor PCC, PCC4 4-factor PCC